Tirzepatide: The Dual-Action GLP-1/GIP Agonist Behind Mounjaro and Zepbound
The first dual incretin receptor agonist to receive FDA approval. How it works, what the clinical trials actually show, and how it compares to semaglutide.
at 15 mg (SURMOUNT-1)
Mounjaro + Zepbound
GLP-1 & GIP
Subcutaneous
Semaglutide changed the obesity treatment world. Tirzepatide raised the bar.
Developed by Eli Lilly, tirzepatide is the first dual GLP-1/GIP receptor agonist to receive FDA approval. It targets two incretin hormones instead of one, and the results speak for themselves: up to 22.5% body weight loss in clinical trials.
It's sold as Mounjaro for type 2 diabetes and Zepbound for weight management. Both names, same molecule.
This is an educational breakdown of tirzepatide, covering its mechanisms, clinical trial data, dosing protocols, side effects, and comparison to semaglutide. It is not a recommendation to use tirzepatide. Always consult a qualified healthcare provider before starting any medication.
Tirzepatide at a Glance
Tirzepatide (Dual Incretin Receptor Agonist)
Type: Synthetic dual incretin receptor agonist | Molecular Weight: ~4,813.45 Da | Developer: Eli Lilly and Company | Brand Names: Mounjaro (T2D), Zepbound (obesity) | Route: Subcutaneous injection, once weekly | FDA Status: Approved for T2D (May 2022) and chronic weight management (Nov 2023) | Primary Actions: Appetite suppression, insulin sensitization, glucose regulation, fat metabolism
Unlike semaglutide, which only hits the GLP-1 receptor, tirzepatide was designed from the ground up as a twincretin. The GIP component isn't an afterthought. It's baked into the molecule's structure.
For a deeper compound profile, visit PeptideArc.
How Tirzepatide Works: Dual Incretin Agonism
Both GLP-1 and GIP are incretin hormones released by your gut after eating. They regulate insulin, appetite, and energy balance. Tirzepatide mimics both of them at the same time.
GLP-1 Receptor Activation
This is the mechanism shared with drugs like Ozempic and Wegovy. GLP-1 agonism suppresses appetite by acting on hunger centers in the brain, slows gastric emptying so food stays in the stomach longer, and stimulates insulin secretion in a glucose-dependent manner.
These effects alone produce meaningful weight loss and blood sugar control. But tirzepatide doesn't stop here.
GIP Receptor Activation
GIP was controversial for years. Some researchers thought blocking it would help with weight loss. Others thought activating it would. Tirzepatide settled the debate in favor of activation.
What the Second Receptor Adds
Appetite amplification: Complements GLP-1's satiety signals through different brain pathways. Insulin sensitivity: Improves how peripheral tissues respond to insulin. Fat metabolism: Directly influences adipose tissue regulation. Beta-cell protection: May protect pancreatic beta cells from dysfunction over time (Samms et al., 2020).
The combination of GLP-1 and GIP produces greater weight loss and glucose control than either pathway alone. That's the entire thesis behind tirzepatide.
The Combined Effect
| Mechanism | Driven By |
|---|---|
| Appetite suppression | GLP-1 + GIP |
| Blood sugar control | GLP-1 + GIP |
| Slower gastric emptying | GLP-1 |
| Insulin sensitivity | GIP |
| Fat tissue regulation | GIP |
| Glucagon suppression | GLP-1 |
The two pathways overlap in some areas and complement each other in others. The result is a drug that consistently beats single-target GLP-1 agonists in clinical trials.
Weight Loss Results: The SURMOUNT Program
SURMOUNT-1: The Headline Trial
This was the trial that made tirzepatide famous for weight loss. Published in the New England Journal of Medicine (Jastreboff et al., 2022).
SURMOUNT-1 Parameters
Participants: 2,539 adults with obesity (BMI 30+) or overweight (BMI 27+) with comorbidity | Duration: 72 weeks | Design: Randomized, double-blind, placebo-controlled | Key exclusion: No diabetes
| Dose (Weekly) | Average Weight Loss | Pounds Lost (at 240 lb) |
|---|---|---|
| 5 mg | 15.0% | ~36 lb |
| 10 mg | 19.5% | ~47 lb |
| 15 mg | 22.5% | ~54 lb |
| Placebo | 3.1% | ~7 lb |
At the 15 mg dose, over one-third of participants lost 25% or more of their body weight. And 63% lost at least 20%.
Bariatric surgery typically produces 25–30% weight loss. Tirzepatide at 15 mg comes remarkably close to that, without the operating room.
SURMOUNT-2: Obesity With Type 2 Diabetes
Weight loss is harder when you have diabetes. Insulin resistance, medications that promote weight gain, and metabolic dysfunction all work against you (Garvey et al., 2023).
| Dose | Weight Loss | HbA1c Reduction |
|---|---|---|
| 10 mg | 12.8% | 2.1 percentage points |
| 15 mg | 14.7% | 2.2 percentage points |
| Placebo | 3.2% | 0.5 percentage points |
Even in a harder-to-treat population, tirzepatide delivered double-digit weight loss.
SURMOUNT-3 and SURMOUNT-4
SURMOUNT-3
Tested tirzepatide after an initial 12-week intensive lifestyle intervention. Combined weight loss reached 26.6% at 15 mg (Wadden et al., 2023).
SURMOUNT-4
Studied what happens when you stop. Participants who switched to placebo regained about half the weight over 52 weeks. Those who continued lost more (Aronne et al., 2024).
Tirzepatide works best as a long-term treatment. Stopping it leads to significant weight regain, consistent with every other obesity medication studied to date.
SURPASS Trials: Diabetes Data
Before it was a weight loss drug, tirzepatide proved itself for type 2 diabetes through the SURPASS program.
| Trial | Comparator | HbA1c Result |
|---|---|---|
| SURPASS-1 | Placebo | Up to 2.07% reduction |
| SURPASS-2 | Semaglutide 1 mg | Tirzepatide superior at all doses |
| SURPASS-3 | Insulin degludec | Tirzepatide superior |
| SURPASS-4 | Insulin glargine | Tirzepatide superior |
| SURPASS-5 | Placebo (add-on to insulin) | Significant additional reduction |
(Del Prato et al., 2021; Frias et al., 2021)
The SURPASS-2 result stands out. It's the only head-to-head trial against semaglutide, and tirzepatide won at every dose for both HbA1c and weight loss.
Dosing: Standard Escalation Schedule
Tirzepatide uses a gradual dose escalation to reduce gastrointestinal side effects. You don't jump to the full dose on day one.
These are the FDA-approved dosing schedules. Always follow your prescriber's instructions.
| Week | Dose | Notes |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Starting dose (not a maintenance dose) |
| Weeks 5–8 | 5 mg | First potential maintenance dose |
| Weeks 9–12 | 7.5 mg | Intermediate step |
| Weeks 13–16 | 10 mg | Second maintenance option |
| Weeks 17–20 | 12.5 mg | Intermediate step |
| Week 20+ | 15 mg | Maximum dose |
Each increase happens every 4 weeks. Some prescribers slow this down if side effects are significant.
Practical Details
How to Take Tirzepatide
Route: Subcutaneous injection (abdomen, thigh, or upper arm) | Frequency: Once weekly, same day each week | Timing: Any time of day, with or without food | Missed dose: Take within 4 days of missed day; if longer, skip and resume schedule | Storage: Refrigerated (36–46°F); room temperature up to 21 days | Device: Pre-filled single-dose pen (no reconstitution required)
Finding the Right Dose
Not everyone needs 15 mg. Many patients find their sweet spot at 10 mg or even 7.5 mg with acceptable weight loss and manageable side effects.
The clinical data shows diminishing returns between doses. Going from 5 mg to 10 mg adds about 4.5 percentage points of weight loss. Going from 10 mg to 15 mg adds about 3 more.
Side Effects and Safety
The side effect profile is dominated by gastrointestinal symptoms, especially during dose escalation.
Common Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Nausea | 24–33% | Most common; usually improves after 2–3 weeks at each dose |
| Diarrhea | 17–23% | More prevalent at higher doses |
| Decreased appetite | 15–20% | Therapeutic effect, but can be excessive |
| Constipation | 11–17% | Can alternate with diarrhea |
| Vomiting | 6–12% | Typically during escalation phases |
| Dyspepsia | 8–13% | Indigestion, heartburn |
| Abdominal pain | 5–10% | Usually mild to moderate |
Less Common but Notable
Occasional Reports
Injection site reactions in about 3–5% of patients. Hair thinning reported anecdotally, likely related to rapid weight loss, not the drug itself. Slight heart rate increase of 2–4 bpm on average.
Gallbladder Events
Gallstones are more common with rapid weight loss, which tirzepatide can certainly cause. Risk increases with higher doses and faster weight loss trajectories.
Severe abdominal pain that doesn't resolve (could signal pancreatitis). Allergic reactions such as facial swelling, difficulty breathing, or severe rash. Vision changes in people with diabetes. Persistent vomiting leading to dehydration.
Dropout Rates
In SURMOUNT-1, discontinuation due to adverse events was 4.3% (5 mg), 7.1% (10 mg), and 6.2% (15 mg) compared to 2.6% for placebo. Most patients tolerate the drug well once they get through escalation.
The slow dose escalation is critical. Patients who rush through it experience significantly more nausea and vomiting.
Tirzepatide vs. Semaglutide
This is the comparison everyone wants. Both are GLP-1 receptor agonists. Both produce significant weight loss. But they're not identical. For a full breakdown, see our semaglutide vs. tirzepatide comparison.
Head-to-Head: SURPASS-2
The only direct comparison trial pitted tirzepatide against semaglutide 1 mg (the diabetes dose, not the 2.4 mg weight loss dose) in type 2 diabetes patients (Frias et al., 2021).
| Metric | Semaglutide 1 mg | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg |
|---|---|---|---|---|
| HbA1c reduction | 1.86% | 2.01% | 2.24% | 2.30% |
| Weight loss | 5.7 kg | 7.6 kg | 9.3 kg | 11.2 kg |
Tirzepatide outperformed semaglutide on both measures at all three doses.
Cross-Trial Comparison
Cross-trial comparisons have real limitations. Patient populations, study designs, and placebo responses differ. The SURPASS-2 head-to-head is the only fair direct comparison, and it used the diabetes dose of semaglutide.
| Feature | Semaglutide 2.4 mg (Wegovy) | Tirzepatide 15 mg (Zepbound) |
|---|---|---|
| Targets | GLP-1 only | GLP-1 + GIP |
| Max weight loss (non-diabetic) | ~16.0% (STEP 1) | ~22.5% (SURMOUNT-1) |
| Trial duration | 68 weeks | 72 weeks |
| Nausea rate | ~44% | ~31% |
| FDA approved (obesity) | June 2021 | November 2023 |
| Administration | Weekly injection | Weekly injection |
| Oral option | Yes (Rybelsus) | Not yet |
| Cost (list price) | ~$1,300/month | ~$1,060/month |
Which One Is "Better"?
It depends on what you're optimizing for.
Tirzepatide Advantages
Maximum weight loss based on available data. GI tolerability may slightly favor tirzepatide at equivalent efficacy. Lower list price than semaglutide.
Semaglutide Advantages
Longest safety track record (approved earlier, more real-world data). Proven cardiovascular benefit from the SELECT trial. Oral availability through Rybelsus.
FDA Status and Availability
Tirzepatide has full FDA approval under two brand names.
| Brand | Indication | Approval Date | Doses Available |
|---|---|---|---|
| Mounjaro | Type 2 diabetes | May 2022 | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| Zepbound | Chronic weight management | November 2023 | 2.5, 5, 7.5, 10, 12.5, 15 mg |
Global Status
United States
Approved (Mounjaro and Zepbound)
European Union
Approved as Mounjaro for T2D (2022); obesity indication approved 2024
United Kingdom
Approved for T2D and weight management
Australia
Approved for T2D
Japan
Approved for T2D
Supply and Access
Tirzepatide experienced significant supply constraints through 2023 and into 2024 due to overwhelming demand. Supply has improved substantially in 2025, though some doses can still be intermittently limited.
Compounded versions were available during the FDA-declared shortage. As Eli Lilly has challenged compounding pharmacies legally, the availability of compounded tirzepatide is shifting. Check current regulations in your area.
Insurance Coverage
Coverage remains inconsistent. Many insurers cover Mounjaro for diabetes but not Zepbound for weight loss. Out-of-pocket costs without insurance run $1,000–1,100 per month at list price, though manufacturer savings programs can reduce this significantly for eligible patients.
Who Might Benefit
Based on the clinical evidence and FDA-approved indications:
Primary Candidates
Adults with BMI 30 or higher seeking pharmaceutical weight management. Adults with BMI 27+ and at least one weight-related condition such as hypertension, dyslipidemia, or sleep apnea.
Also Consider
People with type 2 diabetes who need better glucose control and would benefit from weight loss. Patients who haven't responded adequately to semaglutide and want to try a dual-agonist approach.
Tirzepatide is not recommended during pregnancy, in people with a personal or family history of medullary thyroid carcinoma, or in those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Frequently Asked Questions
What is tirzepatide?
How much weight can you lose on tirzepatide?
How long does tirzepatide take to work?
Is tirzepatide better than semaglutide?
What happens when you stop taking tirzepatide?
Can you drink alcohol on tirzepatide?
Does tirzepatide cause hair loss?
How do you inject tirzepatide?
The Bottom Line
Tirzepatide is the most effective FDA-approved medication for weight loss available today. The dual GLP-1/GIP mechanism produces consistently better results than single-target GLP-1 drugs, with 22.5% average weight loss at the highest dose.
It's not without limitations. GI side effects are common during escalation, long-term cardiovascular outcome data is still pending, and stopping the drug leads to weight regain. Cost and insurance coverage remain barriers for many patients.
But the data is strong, the FDA approvals are in hand, and millions of patients are already using it. For people with obesity or type 2 diabetes who need more than lifestyle changes alone can offer, tirzepatide represents a genuine step forward in treatment options.
This article is for educational and informational purposes only. It is not medical advice and should not be treated as such. Tirzepatide is a prescription medication with real risks and side effects. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Do not use this article as a substitute for professional medical guidance.
References
Samms RJ et al. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410-421. PubMed
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PubMed
Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PubMed
Wadden TA et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Lancet. 2023;402(10418):S3. PubMed
Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48. PubMed
Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021;398(10313):1811-1824. PubMed
Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PubMed
Sattar N et al. Tirzepatide cardiovascular event risk assessment. Nat Med. 2022;28(11):2392-2400. PubMed
Related reading:
What Are Peptides? Beginner's Guide · Semaglutide: Complete Weight Loss Guide · Retatrutide: The Triple-Action GLP-1 Guide · Semaglutide vs. Tirzepatide Comparison
For compound profiles and sourcing info, visit PeptideArc.